El Paso, TX -- (SBWIRE) -- 04/16/2015 -- Premier Biomedical Inc. (OTCQB: BIEI) signed a Patent License Agreement with the University of Texas El Paso (UTEP), covering the cancer treatment process called "CD152-LDMC" which the two entities have been developing in cooperation at the prestigious Border Biomedical Research Center, housed in UTEP's $45-million Bioscience Research Building.

More than 80 faculty members from departments including chemistry, psychology, sociology and biological, geological and mathematical sciences conduct research in the center's labs.

The proprietary process seeks to block a molecule known as cytotoxic T-lymphocyte antigen or CTLA-4, by combining CTLA-4 blocking antibody CD152, along with Low Dose Metronomic Chemotherapy.

Significant progress has been made over the past year advancing the development of CD152-LDMC.

CTLA-4 is believed to play a role in slowing down or turning off the body's immune system, affecting its ability to fight off cancerous cells. CD152-LDMC's goal is to block CTLA-4, allowing the body's immune system to recognize, target, and attack cells in cancerous tumors. The CD152 antibody is similar to the Ipilimumab anti-CTLA-4 antibody (Bristol-Meyers-Squibb's Yervoy®) used for treatment of metastatic melanoma. Ipilimumab and pembrolizumab (Merck's Keytruda®) are the only two cancer immunotherapeutic drugs approved by the FDA to date, both of which are used in the treatment of melanoma.

Dr. Giulio Francia, Assistant Professor at UTEP, said, "We are excited about these preclinical breast cancer studies and on the impact that low dose chemotherapy strategies can have in contributing to the disruption of tumor growth. Ultimately, once approved, such therapies should produce fewer treatment side effects without limiting the clinical effectiveness of the drugs."

Researchers at UTEP have previously presented positive results from duplicated testing of CD152-LDMC on mice at the American Association for Cancer Research annual meeting in San Diego last April. These results showed statistically significant improvements in survival and prevention of breast cancer in mice treated with the CD152-LDMC anti-breast cancer treatment versus chemotherapy-only, and non-treated groups. Most significantly, UTEP has also shown the prevention of breast cancer metastasis in mice.

William A. Hartman, President and CEO of Premier, stated, "This agreement is just the latest step in our positive, on-going working relationship with this outstanding research institute. Dr. Francia and his staff, are world-class researchers, and we are fortunate to be working with them. We look forward to many more such mutually beneficial technological developments."

The process is one of two being jointly studied at UTEP. In addition to CD-152-LDMC, the University is making significant progress with a Sequential-Dialysis machine called the Felder Pathogen Filter (FPF). The company's goal is for the FPF to directly remove metastatic cancer cells, tau proteins, and other harmful substances from the blood for blood-borne diseases and ultimately physically remove the underlying causes of the diseases.

Premier Biomedical is continuing their research at UTEP, as the company believes that this represents a major step in the goal of preventing breast cancer metastasis and defeating cancer in a completely nontoxic manner by utilizing the body's own immune system. Premier has released the photographic results here.

Direct phone inquiries to Premier Biomedical at PBI-MED-7033 (724-633-7033)

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedical.com/

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

El Paso, TX -- (SBWIRE) -- 02/25/2015 -- Premier Biomedical, Inc. (OTCQB:BIEI) announced that they have developed and filed a Request for Designation of Duchenne Muscular Dystrophy as a rare disease, preparing the way for a formal "Humanitarian Use Device" (HUD) application for Premier's treatment and potential cure for the disease. A United States Patent application for this treatment methodology was filed in the third quarter of 2014.

William A. Hartman, President & CEO of Premier Biomedical, Inc., stated, "There is no known cure for Duchenne Muscular Dystrophy, at this time. There are over one million cases worldwide and treatment costs exceed $23 billion annually. Our filing of an application for a Humanitarian Use Device would expedite the availability of this treatment to patients, since the HUD program creates and alternative pathway for getting market approval."

"We are currently awaiting a decision on our Request for Designation of Duchenne Muscular Dystrophy with the FDA," Hartman continued. "Our on-going research and development using our patented technology to cure diseases using antibodies against disease antigens, on bodily fluids treated outside the body, offers hope for those afflicted by this dreaded disease, as well as other incurable diseases."

Duchenne Muscular Dystrophy (DMD) is a recessive X-linked form of muscular dystrophy, and affects 1 in 3,500 births. The condition is mostly seen in males, which results in muscle degeneration and eventual death. Both males and females can carry the mutation; however, females rarely exhibit signs of the disease.

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI" http://www.premierbiomedical.com/

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact:
Premier Biomedical, Inc
W. Hartman
724-633-7033
Email Contact

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

El Paso, TX -- (SBWIRE) -- 01/20/2015 -- Premier Biomedical, Inc. (BIEI) announced that they intend to nationally sell an exclusively licensed and patented drug treatment for fibromyalgia. Premier is submitting documents to the Food and Drug Administration to discuss agency requirements for both clinical studies and eventual marketing approval for this patented drug combination. The drug, Feldetrex®, was issued a patent for its unique combination of FDA approved compounds, in October of 2014.

Feldetrex® is designed to treat the symptoms of fibromyalgia, and will compete with several name brand drugs whose combined annual sales exceed $10 billion. Premier Biomedical has obtained exclusive rights to the Feldetrex® patent.

Premier Biomedical's President & CEO, William A. Hartman, stated that, "This is our second, in a series of filings, we have made with the FDA. Those suffering from fibromyalgia know how painful, debilitating and frustrating it can be to try and manage the symptoms of this widespread disease. We look forward to completing the FDA regulatory process, so that we can get our products into this vast market, and relieve suffering as soon as possible. We intend to capture a share of this ten billion dollar annual market."

"We are very excited about this drug's ability to relieve the symptoms of fibromyalgia, without many of the negative side-effects associated with many of the current drug treatments," said Mitchell S. Felder, M.D., Premier Biomedical's chair of the scientific advisory board.

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact:
Premier Biomedical, Inc.
W. Hartman, 724-633-7033
info@premierbiomedicalinc.com

Source: UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Biomedical, Inc. (OTCBB: BIEI) announced that they developed an Ebola Virus treatment and filed a related Provisional Patent Application

El Paso, TX -- (SBWIRE) -- 01/07/2015 -- Premier Biomedical, Inc. (OTCBB: BIEI) announced that they developed an Ebola Virus treatment and filed a related Provisional Patent Application in the fourth quarter of 2014.Premier Biomedical also submitted the Ebola treatment to the Food and Drug Administration (FDA) to outline requirements for investigational testing to determine both safety and efficacy of the technology.

The technology involved in the Ebola Virus treatment utilizes Premier Biomedical'slicensed patented method to fight disease-causing molecular compoundsoutside of the body by "Physically removing the pathophysiologic basis of disease™." As part of the FDA submission, Premier Biomedical provided 3-D CAD models of its proprietaryhardware and is in the process of producing working prototypes.

Premier Biomedical's President & CEO, William A. Hartman, stated that, "This is the first of a number of filings we plan to make with the FDA in short order. We are pleased with their entire response process,and are anxious to get the FDA regulatory process on a number of biomedical devices and treatmentsbehind us, so that we can get our products tothe market and relieve suffering as soon as possible."

"We are very excited about our breakthrough and innovative technology regarding Ebola," said Mitchell S. Felder, M.D., Premier Biomedical's chair of the scientific advisory board. "Our discussion with the U.S. Food and Drug Administration will further detail the testing requirements to establish safety and efficacy of our proprietary device. We plan to begin that testing process as soon as possible, so that this very promising technology can be marketed to address this desperate global health need."

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

UPTICK Newswire

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

Premier Biomedical, announced the addition of Dr David Vigerust to their Scientific Advisory Board effective immediately.

El Paso, TX -- (SBWIRE) -- 08/18/2014 -- Premier Biomedical, Inc. (OTC-BB: "BIEI") announced the addition of Dr David Vigerust to their Scientific Advisory Board effective immediately. Dr Vigerust will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder.

Dr. Vigerust, MS, PhD is a former Research Assistant Professor of Pathology at Vanderbilt University Medical School and a former Health Research Scientist with the US Department of Veterans Affairs. His research focuses on mechanisms of virus-innate immune response and the pathogenesis of inflammation in tumorigenesis and neurodegeneration. Recent research interests revolve around traumatic brain injury and molecules of the innate immune system. Dr Vigerust received a Bachelors Degree in Biology and Chemistry from the University of Texas at El Paso, a Masters in Microbiology and Immunology from Texas Tech University and a PhD in Cellular and Molecular Pathology from Vanderbilt University and conducted postdoctoral work in Infectious Disease at St. Jude Children's Research Hospital, followed by a second fellowship at Vanderbilt Medical School in Pediatric Infectious Disease. Dr.Vigerust has published in international journals, is an active editor and reviewer for several journals an d was the recipient of several awards for his research over the past 12 years.

William A. Hartman, President & CEO of Premier Biomedical stated, "We are pleased to strengthen our technical staff with the impressive credentials possessed by Dr Vigerust. We will immediately utilize his experience and knowledge to expedite the advancement of our R&D programs on traumatic brain injury, breast cancer, Alzheimer's disease and MS with our partners, the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). We are anticipating several more additions to our Scientific Advisory Board in the very near future." About Premier Biomedical, Inc. Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso and US Department of Defense, initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com

Safe Harbor Notice Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

El Paso, TX -- (ReleaseWire) -- 10/17/2013 -- Premier Biomedical, Inc. has acquired exclusive licenses for patent-pending medications/medical procedures to develop cures for a significant number of the most debilitating and often fatal illnesses affecting mankind: Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI), Multiple Sclerosis (MS), Clinical Depression, and Alzheimer Disease.

Everett Jolly, Editor-In-Chief at Uptick Newswire, recently spoke with William Hartman, President and CEO of Premier Biomedical, Inc regarding their recent work with the US Army and Department of Defense in the treatment of clinical depression and suicide and the relationship to brain trauma. Mr. Hartman shared the company's latest initiative and potential medical breakthrough around the study of brain trauma and the connection to clinical depression and suicide through a partnership with the US Army, Department of Defense, and the University of Texas at El Paso.

"Recently there has also been press on the subject as it relates to brain trauma sustained by NFL players, resulting in a $765 million dollar settlement from NFL team owners to the players union. The impact of brain trauma and its connection to depression and suicide is not mutually exclusive to military trauma", stated Mr. Hartman.

About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/ Lou Gehrig 's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in El Paso, Texas, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI. " www.premierbiomedical.com

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contact Us
Premier Biomedical, Inc.
William A. Hartman, CEO
P.O. Box 31374
El Paso, TX 79930
Email: info@premierbiomedical.com
Website: http://www.premierbiomedical.com
Phone: 724-372-5242

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm